MedTrace Logo

The Açaí Berry COVID-19 Anti-Inflammation Trial

NCT04404218 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2022-05-31

No results posted yet for this study

Summary

The Açaí trial will be testing if the açaí berry extract, a safe natural product with anti-inflammatory properties, can be used as a treatment option in adult patients with COVID-19 in the community.

Conditions

Interventions

DIETARY_SUPPLEMENT

Açaí palm berry extract - natural product

Patients will be prescribed to take 1 capsule (520mg) of Açaí Palm Berry every 8 hours for a total of 3 capsules a day, during 30 days. Total dose: 1,560mg/day of Açaí Berry extract.

OTHER

Placebo

Patients will take 1 placebo pill every 8 hours (total of 3 capsules a day) for 30 days.

Sponsors & Collaborators

  • University of Toronto

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Michael Farkouh, MD, MSc · Peter Munk Cardiac Centre; University Health Network; University of Toronto

  • Ana Andreazza, PhD · Department of Pharmacology & Toxicology; University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-04
Primary Completion
2022-06-15
Completion
2022-12-31

Countries

  • Brazil
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04404218 on ClinicalTrials.gov